Pulmonary Oncology Flashcards

(100 cards)

1
Q

SPN

A

isolated rounded opacity <30 mm on CXR

outlined by normal lung tissue (not in hilar lN)often found incidentally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

malignant causes of SPN

A

primary lung CA (adenoCA)

carcinoid tumor

Metastatic dz (melanoma, colon, breast, kidney, testicular)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

benign causes of SPN

A

Granuloma (infectious process)

benign tumor (hamaratoma, bronchiole adenoma )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

SPN lesion characteristics indicative of malignancy

A
  1. increasing size - rapidly increasing likely CA
  2. SPN composition - solid/subsolid
  3. border characteristics - rougher edges = more likely (corona radiate most)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

SPN risk of malignancy pt characteristics (7)

A
  1. increasing age
  2. smoking
  3. prior malignancy
  4. occupation
  5. female sex
  6. upper lobe lesion
  7. family history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

risk factors for SPN infection

A
  1. immunocompromised
  2. history of TB or other mycosis
  3. residence or extensive travel in areas of endemic mycosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

work up of SPN

A
  1. non-contrast CT (thin cuts)

2. PET/CT scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CT SPN imaging

looking for:

A

benign patterns of calcification

estimation of VDT

malignant patterns

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SPN CT

benign patterns

A

diffuse homogenous calcification

central calficiation

lamellate calcification

popcorn calficiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

estimation of VDT - benign

A

fast ( <30) suggests infection

slow (>480 days)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

malignant patterns of SPN CT

A

peripheral halo

cavitary lesions

Lymphadenopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

solid nodules SPN

A

dense and homogenous

<8mm = too small for bx, less likely to be malignant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

subsolid nodules SOB

A

less attenuation on imaging

normal parenchymal structures can be seen through them

part solid or ground glass (no solid components)

difficult to bx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PET/CT SPN

A

greater than 8 mm

assesses metabolic activity of nodule (most glucose uptake) via SUV

high SUV indicates high FDG, suggestive of malignancy

can exclude cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

management of SPN

A

growing nodule should always be surgically removed ( > 2mm increase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

when is SPN growth considered stable?

A

solid: stable after 24 months no growth
subsolid: 5 yrs no change

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what can we use to determine SPN management?

A

Fleischer guidelines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SPN biopsy

A

sampling to obtain tissue diagnosis

BAL, brushing, directed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

indications for resection of SPN

A
  1. growing legion
  2. high probability of malignancy
  3. metabolically active on PET scan
  4. prior sampling nodule has proven malignant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

bronchogenic lung carcinoma

A

second most common type of CA diagnosed but number one killer of persons (more than colorectal + breast + prostate CA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

lung CA screening

A

should benefit but hard to screen

annual low dose CT screen for HR individuals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

high risk lung cancer defined:

who gets the screening

A

men or women ages 55-79 yrs with 30 pk year history

quit in last 15 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

risk factors for bronchogenic lung cancer

A
  1. smoking (90%)
  2. prior h.o. radiation tx (HL or brest)
  3. environmental exposure (second hand smoke, radon)
  4. Other lung dx, 5. HIV, 6. family history, 7. alcohol and diet
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

epidemiology of bronchogenic lung cancer

A

men > women, lower rates of survival

women: adenoma, high likelihood of local dz, younger age

AA = Caucasian women

AA > men (13% lower)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
classifications of lung CA
1. adenocarcinoma (MC, rising) 2. Squamous cell carcinoma 3. Large cell carcinoma 4. Small cell carcinoma
26
adenosinecarcinoma
mucus gland of bronchi, peripheral nodule predilicition for occurring at pre-existing scars, wounds or inflammation MC found in non-smokers
27
bronchoalveolar cancer
subtype of adenocarcinoma arises form type II pneumocystis profuse, watery sputum spreads alveolarly, present as an infiltrate or as single/multiple nodules
28
squamous cell cancer
CENTRAL portion cavitary lesion in lumen of central bronchus keratin pearls presents as hemoptysis, exfoliates most likely to produce hypercalcemia
29
large cell lung cancer
occurs peripherally lg sheets of atypical cells, focal necrosis (no keratin pearls) SOME = neuroendocrine component (LCNEC)
30
small cell carcinoma
begins centrally, infiltrates mucosa spreads rapidly to hilar and mediastinal lymph node exclusively in smokers small blue CA cells, sparse cytoplasm
31
MC presentation of SCLC
large mediastinal mass with bulky hilar LAD hemoptysis and post obstructive PNA uncommon, narrowing and late obstruction of bronchus neuroendocrine activity
32
small cell carcinoma spread
prone to early hematogenous spread and very aggressive clinical course sensitive initially to CXR but not durable
33
presentation of lung CA
insidious process majority of patients will have advanced dz at diagnosis
34
symptoms of bronchogenic CA (9)
related to primary lesion, spread, distant metastasis, paraneoplastic syndromes 1. new cough/chronic change 2. dry/scantily productive thin mucoid secretions 3. post obstructive PNA with thick sputum 4. dyspnea 5. change in voice 6. hemoptysis 7. chest pain 8. atelectasis, PNA, malignant pleural effusion 9. anorexia/weight loss
35
dyspnea of bronchogenic CA
wheezing and stridor pleural or pericardial effusions (volume loss due to atelectasis) volume loss and atelectasis/lobe collapse
36
chest pain in bronchogenic CA
dull, intermittent pain on side of tumor severe or persistent pain = chest wall or mediastinal invasion
37
SVC syndrome
obstruction of superior vena cava causes 1. superficial venous engorgement of chest 2. facial edema and plethora 3. signs of increased ICP, HA, tinnitus, bursting sensation
38
pancoast's tumor
peripheral tumor (mc NCLC) invade early and cause local destruction invasion of nerves of brachial plexus and cervical sympathetic nerves (stellate ganglion) compression of vascular structures
39
pancoast's tumor syndrome
horner's syndrome severe and unremitting pain (upper back and shoulder w/radiation into axilla down inner aspect of arm to hand) muscle atrophy compression causing edema
40
metastatic dz mc sites
brain, bones, liver, adrenals, pericardium and spinal cord
41
pericardial lesions
heart is unable to expand to produce good CO resulting in tamponade (JVD, HoTN, muffled heart sounds)
42
adrenal lesions
destruction of normal adrenal tissue and adrenal insufficiency HoTN (fluid recesitation decrease), poor stress tolerance, non-specific (weak, tired)
43
symptoms of hepatic metastasis
increased transaminases/LFT's associated with weight loss
44
symptoms of brain metastasis
headache n/v seizures AMS
45
symptoms of spinal cord metastasis
paralysis or peripheral weakness sensory loss of extremity n. invasion = intense pain
46
symptoms of bone metastasis
vertebrae most commonly involved ribs and pelvis primary symptoms: severe pain pathologic fracture may occur
47
paraneoplastic syndromes
organ dysfunction related to immune mediated or secretory effects occurs in 10-20%, may precede, accompany, or follow diagnosis does not indicate metastasis
48
types of paraneoplastics syndrome
SCLC --> SIADH (free water reabsorption) squamous cell --> hypercalcemia (PTHrP) trousseau syndrome (adenocarcinoma) neurological effects (LEMS, SCLC) cushion's syndrome (increased ACTH) SCLC hematologic changes (anemia, thrombocytopenia) digital clubbing
49
work up of lung mass
1. CT w/contrast, entire area 2. CBC, electrolytes, LFTs, LDH, albumin 3. Pulm consult 4. additional testing/tissue diagnosis
50
tissue diagnosis mechanisms
1. fiberoptic bronchoscopy 2. CT guided needle bx 3. FNAB 4. Sputum cytology 5. thoracentesis 6. VATS thoracotomy
51
fiberoptic broncoscapy
direct forceps biopsy, brushing high sensitivity for central, endobronchial lesions US may assist
52
CT guided needle biopsy
evaluation by IR, they skin to get tissue (PTX risk) good for peripheral tissue
53
FNAB
supra-clavicular or cervical lymph nodes diagnostic
54
thoracentesis
malignant pleural effusions, sensitivity 50-60% may perform twice
55
additional testing for suspected lung CA
MRI of brian (CNS symptoms or focal findings) pulmonary function testing evaluation of cardiovascular status PET/CT (look for dz not visible on CT + distant metastasis)
56
which part of node is hardest to visualize on PET/CT?
brain v. difficult bc high uptake of glucose
57
surgical tx options for lung CA
NSCLC 1. Pneumonectomy 2. Lobectomy 3. segmentectomy/wedge resection 4. sleeve resection
58
pneumonectomy
removal of ENTIRE lung MC tumor close to the center of chest
59
lobectomy
removal of an entire lobe containing tumor procedure of choice
60
segmentectomy
part of love removed suboptimal may be used if pt doesn't have enough lung fxn to withstand lobectomy
61
sleeve resection
tx of CA in lg airways resected with clear margins and distal lung reconnected to proximal airway preserves lung function
62
FEV1 and surgery determinations
use PFTs to determine likelihood a patient will come off vent good PFTs = radical surgery
63
chemo for lung CA
4-6 cycles, given over 1-3 days every 3 weeks given MC to pts with NCLC, less successful SCLC
64
radiation for lung CA
radiation delivered to tumor, must pass thru other tissues to reach target successful bc CA cells can''t recover from DNA result
65
differnt types of XT tx
A. conventional external beam: dose fractionation, overtime amount increases B. stereotactic body radiation: fewer tx of beams, go at tumor from multiple angles
66
NSCLC surgery stage I/II
tx with curative intent surgical resection (lobectomy) non-surgical candidates get radiation
67
NSCLC surgery stage III
diverse options, curative intent, mediastinal involvement distinguish none: surgical resection, adjuvant chemo +/- XT involvement: definitive chemo-radiation, becomes modality of choice
68
NSCLC surgery IV
tx is palliative intent (prolong survival) combo platinum based chemo, targeted therapy if possible or after CTX surgical removal of mets
69
driver mutations
tumor growth and progression depend heavily on it blocking signals allows us to have attack o CA with few effects EGFR, ALK
70
EGFR
driver mutation over expresses EGFR MC in women, never smoker, adenoma, asians
71
EGFR targeted therapy
Tyrosine kinase inhibitors first line or second line following initial chemotherapy
72
ALK
direct mutation promoting growth and spread light or never smokers, young its with adnoCA and predicts sensitivity to ALK TKI
73
other forms of target therapy
molecules that block tumor angiogenesis via decreasing BEGF decreases blood supply good option for ALL cancers, not just driver mutations
74
immunotherapy
stimulates immune system to recognize and destroy CA cells PDI ligand is targeted by drugs and destroyed using the body's T cell/CD8 cells
75
PD-1 inhibitors
Pembrolizumab/Keytruda nivolumab/Opdivo Atezolizumab/Tecentriq
76
NSCLC prognosis
HIGHLY lethal TMN stage of cancer at time of diagnosis is most imp. prognostic indicator
77
SCLC stages
limited (ipsilateral hemithorax, regional nodes) 5 yr <17% ``` extensive disease (distant mets, pericardial/pleural, contralateral supraclavicular or hilarious LAD) 2 yr < 5% ```
78
limited SCLC tx
prom tx limited = NO lymph node = surgical resection/lobectomy + chemotherapy
79
limited SCLC + lymph involvement
candidates for chemoradiation any response prophylactic cranial radiation
80
extensive stage SCLC tx
MC presentation systemic chemotherapy, palliative intent if responsive: thoracic XT, prophylactic WBRT
81
palliative care for lung CA
external radiation pain control chemotherapy hospice control
82
external radiation in palliative care
control dyspnea and hemoptysis pain from bony mets obstruction from superior vena cava syndrome symptomatic brain mets
83
chemotherapy palliative care
surgical procedures or chemotherapy to control dz enough to prolong life but no toxicity
84
Neuroendocrine tumors
produce and secrete neuropeptides and neuroamines in a variety of places (GI, lungs) typically slow growing vascular indolent malignant tumors atypical are aggressive and necrotic 1-2% secrete ACTH causing Cushings
85
Neuroendocrine tumors epidemiology
women, caucasians > before age 60 MC lung tumor in children ass. with smoking
86
CT of Neuroendocrine tumors
well circumscribed centrally located males 25% are peripheral SPN
87
bronchial carcinoid tumors symptoms
hemoptysis (vascular tumor) cough focal wheezing recurrent PNA bc tumor grows centrally, obstructing ariway
88
carcinoid syndrome
caused by tumor chemical release, rare in lung NETs (vasoactive instead) flushing, diarrhea, bronchospasm, wheezing, severe hyper-/hypotension octreotide = tx
89
bronchial carcinoid tumors metastasis and diagnosis
mc site of metastasis is liver diagnosed using CT, can do PET-CT serotonin levels unhelpful bc not high enough [ ]
90
tx of bronchial carcinoid tumors
surgical excision adjunct CTX for atypical
91
methods of metastatic spread
hematogenous (via blood) lymphatic (via lymph) direct extension common site bc lungs recieve 100% of blood
92
common primaries in lung metastasis (BReAST)
``` Brest Renal Anal/Colon Skin (multiple melanoma) Testes/ovaries ```
93
metastasis on imaging
multiple sharply demarcated solid nodules/masses Bilateral lower lung fields CXR/CT Lots Little Lower
94
tx of metastasis
find and tx PRIMARY CA appropriately (routine screening) address complications, resection of nodule
95
mesothelioma
primary tumor arising from pleura (also peritoneum, pericardium, testes) begin as a small nodule in lower lung that grows to a sheet encasing pulmonary structures
96
mesothelioma epidemiology
men>women , 50-70 y/o HIGHly associated with asbestos exposure
97
asbestos exposure
20-40 yrs prior to mesothelioma exposure via insulation, shipyard work, building construction and demolition
98
mesothelioma diagnosis
typical pulmonary signs CXR: nodular, irregular unilateral pleural thickening and effusion Contrast CT to show extent, thoracentesis for effusion VATS biopsy to confirm
99
mesothelioma course
progressive hardening to pericardium and diaphragm/abdomen progressive pain and dypsena due to decreased lung expansion
100
staging mesothelioma
thorascopy +/- MRI stage i: completely resected, disease free ii: margins not clear, pleural LAD iii: local extension, mediastinum and chest cavity iv: distant mets